Historical Stock Chart
2 Months : From May 2019 to Jul 2019
By Michael Dabaie
Pfizer Inc. (PFE) said results were positive from a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis.
Patients who achieved low disease activity with Xeljanz extended release 11 mg once daily plus methotrexate after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of Xeljanz as monotherapy. The study demonstrated non-inferiority of methotrexate withdrawal with Xeljanz at week 48, Pfizer said.
The study results will be presented during a late-breaking oral session at the Annual European Congress of Rheumatology in Madrid on June 15.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
June 12, 2019 08:43 ET (12:43 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.